1) Dunn GP, Bruce AT, Ikeda H, et al : Cancer immunoediting : from immunosurveillance to tumor escape. Nat Immunol 3 : 991-998, 2002
2) Bhatia A, Kumar Y : Cancer-immune equilibrium : questions unanswered. Cancer Microenviron 4 : 209-217, 2011
3) Hamanishi J, Mandai M, Iwasaki M, et al : Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci USA 104 : 3360-3365, 2007
4) Li K, Mandai M, Hamanishi J, et al : Clinical significance of the NKG2D ligands, MICA/B and ULBP2 in ovarian cancer : high expression of ULBP2 is an indicator of poor prognosis. Cancer Immunol Immunother 58 : 641-652, 2009
5) Hamanishi J, Mandai M, Abiko K, et al : The comprehensive assessment of local immune status of ovarian cancer by the clustering of multiple immune factors. Clin Immunol 141 : 338-347, 2011
6) Hamanishi J, Mandai M, Matsumura N, et al : Activated local immunity by CC chemokine ligand 19-transduced embryonic endothelial progenitor cells suppresses metastasis of murine ovarian cancer. Stem Cells 28 : 164-173, 2010
7) Dunn GP, Koebel CM, Schreiber RD : Interferons, immunity and cancer immunoediting. Nat Rev Immunol 6 : 836-848, 2006
8) Duncan TJ, Rolland P, Deen S, et al : Loss of IFN gamma receptor is an independent prognostic factor in ovarian cancer. Clin Cancer Res 13 : 4139-4145, 2007
9) Abiko K, Mandai M, Hamanishi J, et al : PD-L1 on tumor cells is induced in ascites and promotes peritoneal dissemination of ovarian cancer through CTL dysfunction. Clinic Cancer Res 19 : 1363-1374, 2013
10) 万代昌紀,濱西潤三,松村謙臣,他 : 婦人科がん免疫療法の光と影―3 がん免疫療法の未来.産婦の実際59 : 795-800,2010